Panel Discussion: Expanding the Obesity Drug Development Pipeline from Peripheral Targets to Holistic Metabolic Health
- Exploring beyond traditional targets to understand how peripheral pathways and novel mechanisms address unmet needs in obesity care
- Integrating multi organ approached from gut-brain signalling with systemic metabolic health for synergistic efficacy to address payer demands, and drive adherence and market access
- Translating preclinical insights into clinically viable non-incretin therapies to diversify obesity drugs and move from placebo to active comparator trials